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ABSTRACT 
 
Clinically isolated syndrome (CIS) patients present with a single attack of inflammatory 
demyelination of the central nervous system. Recent advances in multiple sclerosis (MS) diagnostic 
criteria have expanded the number of CIS patients eligible for a diagnosis of MS at the onset of the 
disease, shrinking the prevalence of CIS. MS treatment options are rapidly expanding, which is 
driving the need to recognise MS at its earliest stages. In CIS patients, finding typical MS white 
matter lesions on the patient’s MRI scan remains the most influential prognostic investigation for 
predicting subsequent diagnosis with MS. Additional imaging, cerebrospinal fluid and serum testing, 
information from the clinical history and genetic testing also contribute. For those subsequently 
diagnosed with MS, there is a wide spectrum of long-term clinical outcomes. Detailed assessment at 
the point of presentation with CIS provides fewer clues to calculate a personalised risk of long-term 
severe disability. 
 
Clinicians should select suitable CIS cases for steroid treatment to speed neurological recovery. 
Unfortunately, there are still no neuroprotection or remyelination strategies available. The use of 
MS disease modifying therapy for CIS varies amongst clinicians and national guidelines, suggesting a 
lack of robust evidence to guide practice. Clinicians should focus on confirming MS speedily and 
accurately with appropriate investigations. Diagnosis with CIS provides an opportune moment to 
promote a healthy lifestyle, in particular smoking cessation. Patients also need to understand the 
link between CIS and MS. This review provides clinicians an update on the contemporary evidence 




Clinically isolated syndrome (CIS) describes a solitary clinical event, of inflammatory demyelinating 
aetiology, affecting the central nervous system (CNS) and is frequently the first attack of multiple 
sclerosis (MS). CIS is a shrinking concept because of changes in the 2017 modified McDonald 
diagnostic criteria for MS.1 The availability of MS disease modifying therapy (DMT) and the 
suggestion that its clinical impact may be greatest if used at the earliest stages of the illness has 
driven the need to identify those patients who will go on to be diagnosed with MS at an earlier time 
point in order to initiate DMT.  
 
A CIS patient typically presents subacutely, with a monocular optic neuritis, focal supratentorial 
syndrome, brainstem or cerebellar syndrome, or partial myelitis. Symptoms of CIS must occur in the 
absence of fever, infection or encephalopathy and last more than 24 hours, but typically last for 
several weeks, before partial or complete remission. The past medical history of anyone presenting 
with CIS needs to be explored in detail, to ensure their presentation is a solitary clinical event and 
they do not already have MS. Of those who are later diagnosed with MS, up to one quarter of CIS 
presentations are multifocal e.g. an optic neuritis with relative afferent pupillary defect, but also a 
Babinski sign.2 MS is the recurrence of this autoimmune demyelinating process, disseminated in 
both time and location within the CNS. While the cause of CIS and subsequent MS is not fully 
elucidated, it appears that pervasive environmental triggers in genetically susceptible individuals 
leads to the disease. The median age at presentation is approximately 30, and epidemiological 
studies show the prevalence and in some countries the incidence of MS is increasing. In 2016, the 
prevalence was estimated to be 165 and 127 per 100,000 in North America and Western Europe 
respectively.3 There is an increasing female to male ratio of patients, now estimated to be between 
2:1 and 3:1.2, 4 
 
Table 1 
How to diagnose multiple sclerosis. Adapted from the 2017 modified McDonald criteria1 
 
Number of clinical attacks 
Number of lesions with 
objective clinical evidence 
Additional data needed for a diagnosis of 
multiple sclerosis 
≥2 ≥2 None 
≥2 
1 (as well as clear-cut 
account of a previous 
attack involving a lesion 
in a distinct anatomical 
location) 
None, however, caution is needed when 
considering historical attacks in the 
absence of residual neurological deficit 
on examination, to avoid misdiagnosis 
≥2 1 
Dissemination in space demonstrated by 
an additional clinical attack at a different 
CNS site or by MRI showing typical MS 
lesions in multiple locations 
1 ≥2 
Dissemination in time demonstrated by 
an additional clinical attack or by MRI 
showing simultaneous contrast 
enhancing and non-enhancing MS 
lesions or by an interval MRI with new 
MRI lesions or by detecting OCB 
1 1 
Dissemination in space demonstrated by 
an additional clinical attack at a different 
CNS site or by MRI showing typical MS 
lesions in multiple locations 
AND 
Dissemination in time demonstrated by 
an additional clinical attack or by MRI 
showing simultaneous contrast 
enhancing and non-enhancing MS 
lesions or by an interval MRI with new 
MRI lesions or by detecting OCB 
CNS – central nervous system, MS – multiple sclerosis and OCB – unpaired oligoclonal bands 
 
The 2017 modified McDonald criteria, summarised in Table 1, allow clinicians to substitute clinical 
evidence of dissemination in space with MRI evidence of typical lesions in multiple CNS locations. A 
typical MRI lesion is defined as ovoid or round, hyperintense on T2-weighted MRI and at least 3mm 
in its long axis. Lesion location is also important, with periventricular lesions, regularly involving the 
corpus callosum, being more specific. A second clinical event providing evidence of dissemination in 
time can now be substituted with simultaneous contrast enhancing and non-enhancing MRI lesions, 
development of new MRI lesions on serial scanning or demonstration of unpaired oligoclonal bands 
(OCB) in the cerebrospinal fluid (CSF) that provide supporting evidence of the immune and 
inflammatory nature of the disease.1 
 
Approximately 10-15% of patients with MS have primary progressive MS, with slowly progressive 
neurological disability from onset, and paraclinical evidence of MS pathology.5 Radiologically isolated 
syndrome is an incidental imaging finding consistent with MS lesions, but no history of CIS or MS 
relapses. It increases the risk of subsequently developing MS.6 However, detailed discussion of these 
is beyond the scope of this review. In addition, numerous articles describe the differential diagnosis 
of CIS and the many mimics that clinicians should be mindful of to avoid misdiagnosis.7 To this end, 
clinicians should only apply the 2017 modified McDonald criteria to cases of typical CIS, described 
above. The criteria were created to maximise their sensitivity, at the cost of reduced specificity. Thus 
they are only suited to application in cases which already have a high likelihood of being MS. When 
the patient is from a low risk group or there are atypical clinical features the clinician should 
consider additional investigations for relevant MS mimics, using a higher threshold for the number 




Prognostication in CIS patients is divided into prediction of subsequent diagnosis of MS and the 
longer-term prediction of severe disability in those with MS. These risks are linked to prevalence of 
MS in the population from which the patient is drawn and the definition of MS that is used. Most CIS 
prognostication studies have been conducted in young, predominantly Caucasian adults from 
countries with the highest global burden of MS and will not reflect the risks when applied outside of 
these populations. These studies applied older disease definitions, which diminishes their 
applicability to modern CIS cohorts. There is emerging evidence that modern MS cohorts may 
experience a more benign course, independent of MS DMT use. 
 
Prognostic factors for developing multiple sclerosis – routine clinical use 
Approximately one third of CIS patients do not have a chronic disease and are never diagnosed with 
MS, even with follow up lasting up to 30 years.8, 9 The single most important paraclinical test in CIS 
patients is MRI. Detection of MS lesions on baseline brain MRI increases the long-term risk of having 
a second clinical event to 80%, while detecting no MRI lesions reduces the risk to 20%.10 The risk of 
early MS (being diagnosed within five years) is higher with increasing MRI lesion load, greater than 
three periventricular lesions or infratentorial lesions.8, 11, 12 Spinal lesions on MRI can assist in 
fulfilling the McDonald criteria of radiological dissemination in space and increase the risk of early 
MS.13 The presence of simultaneous gadolinium enhancing and non-gadolinium enhancing lesions 
are sufficient to substitute for the requirement of a second clinical event as they are strongly 
associated with future radiological and clinical disease activity.1 However, it is estimated that 10-15% 
of patients with CIS will only develop new radiological lesions, and not have a second clinical event 
consistent with a relapse, with follow up lasting up to 20 years.12 
 
Lumbar puncture demonstrates unpaired, CSF specific, OCB in two-thirds of CIS patients. In these 
cases, two-thirds are subsequently diagnosed with MS, while only one-fifth of OCB negative cases 
are.14 However, the risk of MS is substantially modified by the patient’s MRI findings, and when this 
information is considered together in a multivariate model, OCB predictive power is modest. OCB 
positivity has a hazard ratio below two, while MRI lesions have a hazard ratio of 5-10 dependant on 
increasing lesion number.12 OCB testing has its largest prognostic impact in those CIS patients who 
do not have MRI lesions at baseline. Some centres assess the IgG index to produce a quantitative CSF 
measure, when abnormal it has a similar hazard ratio for MS as OCB, but given its lower sensitivity, 
offers little additional information from OCB assessment using isoelectric focussing. Unpaired OCB 
are now an alternative way to confirm MS in patients who have already demonstrated dissemination 
in space.1 The inclusion of this criterion in the latest iteration of the McDonald criteria has led to a 
substantial increase in patients with CIS being eligible for a diagnosis of MS at presentation. In one 
study, only half of this newly defined group had a clinical relapse within five years of follow up.15 It is 
unclear whether this was due to short follow up, MS DMT use or misdiagnosis as MS. If significant 
numbers of CIS patients who never have a second clinical event are labelled as MS, then modern MS 
cohorts will have a milder disease course. 
 
Clinical factors have less impact on the risk of MS, with natural history studies frequently resulting in 
conflicting conclusions. However, there is an increased risk with younger age, while atypical features 
of the CIS presentation make MS less likely.11 A meta-analysis of the effect of gender showed a 20% 
increase in the relative risk for women compared to men, but this effect did not reach statistical 
significance.4 
 
Prognostic factors for developing multiple sclerosis – emerging evidence 
Additional information can be gained when advanced sequences are included in the baseline CIS MRI 
scan. Alternative CSF markers of immune activation within the CNS have also been investigated for 
their prognostic value. Most recently, serum markers of neural degeneration have attracted intense 
interest given the relative ease of acquiring samples, even if the assay technologies are not yet 
standardised or widely available. Clinical information may offer prognostic clues if features have 
been objectively associated with disease pathogenesis. Lastly, genome-wide association studies have 
demonstrated the impact of immune genes on the risk of MS. 
 
The central vein sign demonstrates the pathologically characteristic perivenular MS lesion 
distribution. Cross sectional and small longitudinal studies demonstrate its role as a diagnostic 
biomarker when greater than 40% of white matter lesions have a visualised central vein, though it is 
not pathognomonic.16 Its prognostic role is only inferred, and large prospective longitudinal studies 
to assess this are now underway e.g. DECISIve NCT04024969. Several MRI sequences can be used to 
visualise the central vein sign, with T2* the simplest to implement clinically. Numerous MRI 
sequences are available to demonstrate additional elements of MS pathology in vivo. Structural MRI 
(T1 weighted sequences) can demonstrate grey matter atrophy, which is predictive of early diagnosis 
with MS.17 Magnetisation transfer ratio and inversion recovery MRI sequences improve 
quantification of myelination status and the detection of cortical lesions respectively.18 This has led 
to the inclusion of cortical lesions in the 2017 modified McDonald criteria as a site to demonstrate 
radiological dissemination in space. Magnetisation transfer sequences have yet to be implemented 
in routine clinical practice because acquisition and interpretation are more challenging. Magnetic 
resonance spectroscopy and functional MRI currently have no clinical role in managing CIS patients. 
The changes observed with these MR modalities in CIS or MS are subtle. There are disagreements 
about the temporal evolution of abnormalities, and there is a lack of reproduction in larger studies.19 
Optical coherence tomography (OCT) is sensitive enough to monitor the effect of optic neuritis and 
be considered a surrogate endpoint for optic neuritis treatment trials.20 It can be used, like visual 
evoked potentials, as supportive evidence, when a CIS patient reports an historic episode consistent 
with optic neuritis, but they do not have objective signs on clinical examination.1 OCT may be similar 
to measuring atrophy with structural MRI. A thinner retinal nerve fibre layer, when there is no 
history of optic neuritis, has been associated with a higher risk of conversion to MS.21 However, 
pathological findings are not specific to MS.  
 
The CNS should be relatively immune privileged. Hence, when performing a univariate analysis in 
carefully selected high-risk CIS cases, markers of both the adaptive and innate immune response in 
the CSF often appear to demonstrate prognostic significance. The problem with these markers, 
including unpaired OCB, is that they are not specific to MS. Clinicians must be mindful that these 
results could be associated with other long-lived neuroinflammatory or infective responses. For 
example, unpaired OCB are detected in half of patients with neurosarcoidosis and one fifth of 
patients who have had a stroke. While OCB are imperfect, they have the highest accuracy of the CSF 
markers so far tested. These include IgG ratio, IgM production, measles, rubella and zoster 
antibodies, chemokine ligand 13, kappa and lambda light chain, complement levels, chitotriosidase 
and chitinase 3-like 1.22-31 CSF cell count is routinely available, making CSF pleocytosis an attractive 
potential biomarker; however, it is not consistently associated with an increased risk of MS.11 A 
newer approach is to use proteomics or neurometabolomics in the hope that the CSF MS signature 
will be more specific, and recognisable at the point of presentation with CIS. The very early work to 
date with these techniques is promising, but the time and cost of sample processing and analysis will 
have to be significantly reduced prior to its consideration for clinical implementation.32 
 
MS is a neurodegenerative condition, in addition to the principal inflammatory component. Markers 
of neural degeneration that have been assessed in the CSF include neurofilament heavy and light 
chain, tau protein and glial fibrillary acidic protein.33, 34 Of these, neurofilament light chain has shown 
the most promise as a prognostic biomarker. With an ultra-sensitive assay, serum levels can be 
monitored conveniently. Ongoing research aims to characterise appropriate age adjusted normal 
cut-off values and the range of comorbidities that influence it. After this, appropriately powered 
research will still need to demonstrate that it offers independent prognostic information from those 
factors considered above.  
 
The presence of subtle cognitive impairment at presentation may suggest chronicity of the disease 
process and is associated with a small increase in the risk of MS.35 There is limited evidence that non-
Caucasian ethnicity is also associated with an increased risk.36 Individual studies have come to 
conflicting conclusions about whether CIS site, including whether the clinical syndrome is monofocal 
or polyfocal, influences MS risk.10, 36 Higher Epstein Barr virus antibody titres may have a modest 
impact.37 Tobacco smoking and low Vitamin D serum levels are modifiable risk factor that have been 
associated with an increased risk of MS.38, 39 Obesity during adolescence, particularly in women, is 
associated with a higher incidence of MS, rather than directly being linked to MS risk in CIS 
patients.40 
 
Using genome wide association studies more than 200 genetic variants have been associated with 
MS disease susceptibility so far, ∼90% of which are noncoding.41 Genes controlling all major immune 
cells are implicated and microglia are, genetically, the most important CNS cell type. Many genetic 
variants associated with MS risk are also found in other autoimmune diseases. HLA-DRB1∗15:01 is 
the strongest single genetic risk factor for MS in those of European ancestry. Carriers have an odds 
ratio of three for developing MS and it has a small prognostic role when tested at presentation with 
CIS.42 It is found in over 10% of the population with European ancestry. However, despite this testing 
is not routinely offered at present.  
 
Although these imaging, CSF, serum, clinical and genetic factors have all been associated with 
increased risk of MS, the most robust predictor remains conventional MRI abnormalities. Thus, when 
considering all information about a patient, these additional factors only have a modest role in 
prognostication. Instead, their role lies in helping us to understand the heterogeneous MS disease 
process. They can contribute to the effort of developing DMT and possibly one day in selecting MS 
sub-populations for those treatments, so called personalised medicine. In addition, these factors 
have rarely been studied in aggregate, so there is likely co-linearity, and research has not always 
been performed in representative populations. Future prognostic studies need to adopt robust 
methodologies and recruit representative participants across multiple centres. 
 
Summary: 
• MRI is currently the most important prognostic test for CIS patients 
• OCB can now be substituted for clinical or radiological evidence of dissemination in time 
• Atypical features of the CIS presentation make MS less likely, but other clinical factors 
have little prognostic impact 
 
Prognostic factors for worse disability in those with multiple sclerosis – routine clinical use 
Classic natural history studies, in predominantly untreated patients, suggested that for those who do 
have MS after twenty years 30-40% of patients will still be fully ambulatory, 10-20% will have died 
due to MS and the remainder will have restricted ambulation, require an aid to walk, use a 
wheelchair or be immobile and almost all of these will have secondary progressive MS (SPMS).9, 10 
However, these estimates are now outdated with MS becoming a milder disease.43 This may be due 
to the shifting diagnostic definition, improvements in population life expectancy or the widespread 
availability of over a dozen DMTs. Only the injectable therapies have long-term follow up data on 
disability endpoints, but the favourable comparison with historic controls may be biased for the 
other reasons listed. 
 
MS is a challenging neurological condition on which to prognosticate, given it is often decades 
between onset with CIS and severe disability. Most research studies compare baseline factors to the 
number of early clinical relapses, new radiological lesions, or disability at five years from onset. This 
is despite only one fifth of patients rapidly acquiring permanent disability during the relapsing 
remitting phase of the illness.44 For most patients the accumulation of disability is detected when 
transitioning from the initial relapsing remitting phase to SPMS. While fewer studies are available to 
inform us about this, baseline factors are only modest predictors of long-term outcome for 
individual patients. The same risk factors appear to be associated with death due to MS, significant 
disability and chances of developing SPMS. 
 
While MRI abnormalities at presentation with CIS are the single most important determinant of the 
risk of MS, their association with long-term disability is limited. However, lesions on the baseline CIS 
scan affecting the brainstem and spinal cord are associated with worse prognosis.13 The presence of 
gadolinium enhancing lesions and cortical lesions at baseline have some evidence to support an 
association with worse prognosis.45 While not available at the point of presentation, increasing T2 
lesion volume over time, particularly in the first five years, is the MRI measure best correlated with 
long-term disability that is routinely available clinically.10 
 
Presence of OCB at lumbar puncture is associated with a slightly worse disease course compared to 
OCB negative cases in many studies.46 
 
Male sex is sometimes associated with a slightly worse prognosis in MS, but several papers have 
reported no significant difference. Incomplete recovery from the CIS attack and sphincter or motor 
involvement at onset are more often found to be associated with poorer outcomes.9, 45 The role of 
age at CIS is debated. Time from diagnosis to SPMS is often found to be shorter in older onset CIS 
patients, but is less useful than comparing age on reaching SPMS, which shows younger onset CIS 
patients have a worse prognosis.47 The most important clinical factor is the number of early relapses, 
again something not possible to determine at first presentation with CIS.45  
 
Currently none of the information available at presentation has sufficient prognostic value to 
provide individual patients a personalised estimate of future disability at presentation with CIS. After 
five years of clinical and radiological monitoring patients can be split into three groups. A low-risk 
group with no disease activity or adverse features and likely minimal disability for decades. This low-
risk group remain vulnerable to transition to SPMS the longer they are followed, and MS may have a 
significant impact on their cognition or employment while they are still in the relapsing remitting 
phase.48 The majority will be in an intermediate risk group. Up to one fifth will be in a rapidly 
progressive high-risk group, with significant radiological and clinical MS activity, in whom severe 
disability or death due to MS is a common outcome. Several prognostic tools exist to apply this 
information in a clinical setting. However, before using these tools to advise patients about 
treatment decisions, it is worth considering that their development and testing utilised relatively 
small datasets, consequently they are less robust than other risk scoring tools in routine clinical 
practice.49 Instead, some clinicians rely solely on the information from the CIS baseline MRI to guide 
treatment decisions.  
 
Prognostic factors for worse disability in those with multiple sclerosis – emerging evidence 
Given the widespread availability of DMT there will not be further natural history studies in 
untreated MS. Instead, contemporary observational cohorts should continue to pool data to identify 
new prognostic factors that predict death due to MS, significant disability and chances of developing 
SPMS despite DMT use. This is important for two reasons. First, prognostic studies for MS show 
improving outcomes over time, and our patients need timely access to this updated information. 
Second, misidentification of the relative importance of prognostic factors can distort clinical decision 
making towards targets that do not influence the most important outcome of interest, long-term 
disability. 
 
When considering information gathered in the first years of MS from MRI, brain atrophy will likely 
surpass the prognostic role of new focal lesions or measuring increasing T2 lesion volume.50 
However, measurement is currently only available in a small number of MS centres and it appears 
that global atrophy might be less important than grey matter atrophy. It is also necessary to 
distinguish MS related brain atrophy from normal ageing.51 More advanced MRI techniques such as 
magnetisation transfer ratio and magnetic resonance spectroscopy have not been associated with 
worse disability in the short-term.17 
 
In addition to the presence of OCB in the CSF, an increasing number of visualised bands, higher IgG 
or IgM index and higher CSF cell count may reflect disease that is more active and be relevant to 
prognosis.46, 52 High levels of kappa light chains and chemokine ligand 13 have each been associated 
with worse prognosis in small studies. However, one of the strongest CSF predictors of worse 
medium-term disability seems to be high CSF neurofilament light chain.53 While it is hoped that 
baseline, or serial serum neurofilament measurement will provide independent long-term 
prognostic information, this has not been consistently demonstrated.54 
 
Optic neuritis or sensory-only CIS, complete recovery from CIS and a longer period to the second 
clinical event have all been associated with less long-term disability, but not consistently across 
studies. Late relapses, beyond five years of diagnosis, are not reported as associated with worse 
disability. However, one study found relapses between 10-15 years after MS diagnosis were still 
responsible for a third of disability accumulation in that period.55 Smoking status and low Vitamin D 
levels are predictive of short-term relapsing MS activity; however, their association with worse long-
term disability has not been demonstrated.56 Non-Caucasian ethnicity may predispose to worse 
disability, if confirmed the contributors to this association require further investigation. For women, 
nulliparity is associated with worse disability, however this phenomenon may be due to reverse 
causation.  
 
Hopefully, the widespread use of electronic healthcare records will drive further improvements in 
our understanding of prognostic factors linked to long-term, clinically meaningful endpoints. One 
difficulty with drawing inferences from observational data is how to account for the indication for 
why a given DMT was chosen, so datasets should consider collecting this information. Most of the 
long-term prognostication studies available included patients for whom higher-efficacy DMT was not 
available in the crucial early years of their disease or followed past treatment algorithms, making 
them unsuitable for prognostication of modern cohorts.  
 
Summary: 
• Personalised prediction of long-term disability at presentation with CIS is challenging but is 
improved by close clinical and radiological monitoring 
• Observational data shows outcomes are improving, even prior to widespread DMT use 




The management of an acute inflammatory CNS insult in CIS is no different from the management of 
an MS relapse. Recovery can be accelerated with high dose steroids. Traditionally this has been 
given in the form of a short three to five-day course of 1000 milligrams intravenous 
methylprednisolone following the Optic Neuritis Treatment Trial. However, several recent studies 
have suggested non-inferiority between oral and intravenous methylprednisolone, the main benefit 
of which is ease of outpatient administration.57 Treatment shortens the duration of neurological 
symptoms, but it does not improve the level of neurological recovery and is therefore not universally 
required. Patients should be counselled about the myriad side effects of steroids, many of which are 
related to the cumulative lifetime dose. Like all disabling inflammatory CNS relapses, plasma 
exchange can be used when steroids fail to show improvement.  This treatment has a clear role in 
antibody-mediated diseases such as neuromyelitis optica, but there is less published evidence of 
benefit in CIS.58 Many neurologists, and the authors of this review, instead typically use a second 
course of steroids and only if there is minimal improvement consider five cycles of plasma exchange, 
although no evidence exists to support the superiority of this approach. If there is no response to the 
first course of steroid, the possibility of misdiagnosis should be reconsidered. Intravenous 
immunoglobulin should not be used for the treatment of CIS.59 
 
On many occasions, the clinical presentation and MRI findings are typical of MS and meet 
dissemination in space criteria, but dissemination in time has not been demonstrated. Clinicians 
frequently feel confident that this patient group will be given a diagnosis of MS, either by detecting 
OCB or new MRI or clinical activity over the next few months or years. A clear indication of the very 
likely outcome and final diagnosis needs to be given to the patient in these circumstances. This is 
while recognising that misdiagnosis persists despite, or partially due, to easier access to MRI. 
Screening for aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies should occur if 
neuromyelitis optica spectrum disorder or myelin oligodendrocyte glycoprotein antibody associated 
disease are considered differential diagnoses.60 Clinicians may feel that patients subconsciously exert 
pressure looking for definite answers, but it is inadvisable to immediately issue an unequivocal 
diagnosis of MS if patients do not explicitly meet diagnostic criteria. Particularly in the current 
treatment era in which some DMTs have rare, but more serious risks than in the past.7 Misdiagnosis 
may also have negative psychological and material impacts such as obtaining insurance or a driving 
licence. 
 
After the acute phase of CIS management, the next decision is whether to commence MS DMT. 
When given at presentation, injectable DMT delays clinical diagnosis with MS. However, the long-
term benefit of this approach over waiting to use DMT until MS is diagnosed is uncertain.61 The 
practice of treating CIS varies in different countries and amongst neurologists. It has consistently 
produced debates in MS meetings. In the latest iteration of the McDonald diagnostic criteria, the 
inclusion of OCB to substitute for evidence of dissemination in time facilitates faster diagnosis and 
has reduced the prevalence of CIS patients. Older trials showing DMT delays conversion from CIS to 
MS include a substantial proportion of patients who would now instead be diagnosed with MS at 
presentation. Therefore, those diagnosed as CIS now have greater uncertainty as to their final 
diagnosis, making early treatment with MS DMT more difficult to justify. If a lumbar puncture, or 
possibly central vein imaging, is to be arranged, most clinicians would withhold starting DMT prior to 
the results being known. If unpaired OCB are not present or the lumbar puncture procedure is not 
successful, the clinician must balance the risks of probable lifelong DMT treatment with the 
alternative of initiating treatment after a few months delay to allow diagnostic confirmation. Repeat 
MRI to look for dissemination in time before treatment is initiated is usually a safer option than 
starting treatment blindly. Unfortunately, despite increasing numbers of exploratory trials, no 
neuroprotection or remyelination therapies suitable for use in CIS have yet been developed. 
 
When a CIS patient does develop MS, the optimum management with MS DMT is also a contentious 
area. Two large Phase 4 studies; DELIVER-MS NCT03535298 and TREAT-MS NCT03500328 are 
currently underway to help address this uncertainty. 
 
The diagnosis of CIS offers an opportunity to discuss healthy lifestyle choices. Despite the association 
between MS risk and smoking status and low Vitamin D levels, randomised controlled trials have 
failed to show a clear benefit from intervention.56 These were predominantly small studies, 
conducted in MS rather than CIS. Therefore, clinical practice should be to offer smoking cessation 
services due to the benefit to the patients' overall health, while the specific benefit for this and 
supplementing Vitamin D in CIS is still being investigated.  Given the impact of medical co-
morbidities on long-term outcomes weight management (avoiding both extremes), improving diet, 
exercise and sleep are steps that patients can take to improve their health, if they understand no 
intervention has been studied in a robust fashion to establish its impact on MS course. This is more 
likely to be achieved by setting specific goals for behaviour change. 
 
Summary: 
• Use methylprednisolone for significantly disabling CIS symptoms 
• Although early treatment in MS appears advantageous, initiation of DMT for CIS is still 
controversial 
• Promote healthy lifestyle choices, most importantly smoking cessation 
  
WHAT PATIENTS SHOULD BE TOLD 
 
Understandably, a barrage of questions from the patient often immediately follows the diagnosis of 
CIS. Is CIS the same as MS, will I become disabled, could it be another disease and what treatment 
will I receive now? It is important to adjust the tone of the initial consultation depending on the 
certainty of diagnosis. From this dialogue, patients will have the context to interpret their test 
results in subsequent consultations. The first step in clinical management of CIS must be to make an 
accurate diagnosis, excluding common mimics of the condition, and to communicate effectively with 
patients. Many patients do not fully understand the link between CIS and MS.62 The fluctuation of 
symptoms and pseudo-relapses needs to be addressed as they frequently generate a lot of anxiety. 
This is in addition to ensuring patients recognise clinical relapses and report them promptly to the 
MS team. 
 
Online resources about CIS and MS should be offered for the patients that would like more 
information, in addition to their consultations with neurologists and MS specialist nurses. Not all 
patients will want this extra reading but signposting them to reliable resources (frequently national 
MS societies) reduces the risks from unreliable health websites and social media. The psychological 
impact of receiving a diagnosis of CIS, which on many occasions is heard by the patient as akin to a 
diagnosis of MS, should not be underestimated. Patients often remember the words used and 
support given at the first consultation for the rest of their life. The MS team can provide initial 




• Explain the link between CIS and MS to patients with CIS 
• Warn patients they may experience pseudo-relapses or symptom fluctuations as well as 
relapses 





Our ability to offer an individualised prognosis for CIS is reliable when we consider the risk of 
subsequent diagnosis of MS, but poor when we consider disability at twenty years after diagnosis. 
MRI remains the key prognostic test for these patients, while the clinical role of supplementary CSF 
and blood tests continues to develop. Acutely the treatment for CIS remains the same as for MS 
relapses. The increasing range of DMT options and the recognition that their benefit with respect to 
long-term outcomes appears greatest when given early in the MS disease course is driving the need 
for earlier recognition of MS. However, we must accept that broadening the definition of MS will 
create more patients with better outcomes regardless of DMT use. Our patients require information 
about CIS and MS at first presentation, and most will want to discuss their personalised prognosis 
before making treatment decisions. This gap between our patients’ expectations and our current 
knowledge should be the focus of ongoing prognostication studies and randomised controlled trials 
of different DMT regimes. 
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